Company: SHPH
Filing Date: 2025-02-13
Form Type: S-1
Source: 0001493152-25-006202
Chunk: 20

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-13
Form: S-1
Chunk 20
---
 the conversion price will be the lower of a 15% discount to (i) the
5-day VWAP immediately prior to Closing or (ii) the price of any offering entered into by the Company during the term of the notes. The
Company has the option to prepay the notes at any time for 107% of total outstanding balance and any outstanding principal will be paid
in conversion of shares of common stock at the end of the term, subject to the Company’s exercise of the optional prepayment right.
Any accrued interest will be repaid quarterly in cash. The Company also issued warrants to the lenders to purchase an aggregate 240,917
shares of common stock, exercisable at $1.40 per share, with such warrants expiring five years from issuance. In addition, the Company’s
Chief Executive Officer, Dr. Anatoly Dritschilo, invested a total of $237,500 in this financing round, in exchange for a $250,000 convertible
note.

On October 21, 2024, the Company issued an additional
$231,579 in senior secured convertible notes due in October 2025, with substantially similar terms as the October 14, 2024, issuance.
The notes include a 5% original issue discount and the Company received $220,000 in proceeds. The Company also issued warrants to the
lenders to purchase an aggregate 88,544 shares of common stock, exercisable at $1.49 per share, with such warrants expiring five years
from issuance. Upon completing this issuance, the Company closed the senior secured convertible note offering after receiving a total
of $790,000 in proceeds

| 8 |

Summary Risk Factors

Our business is subject to a number of risks you should be aware of before making an investment decision. These risks are discussed more fully in the “Risk Factors” section of this prospectus at page 13 immediately following this prospectus summary, and in Part I, Item 1A “Risk Factors” of our Amended Annual Report on Form 10-K/A for the fiscal year ended December 31, 2023, as amended on September 3, 2024, and in Part II, Item 1A “Risk Factors” of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, which are each included in this prospectus. These risks include the following:

| ● | Our                                                                                                                                       
 ability to continue as a going concern in the